北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy
作者: Liu, Shiwei1; Duan, Xuening1; Xu, Ling1; Xin, Ling1; Cheng, Yuanjia1; Liu, Qian1; Ye, Jingming1; Zhang, Shuang2; Zhang, Hong2; Zhu, Sainan3; Li, Ting2; Liu, Yinhua1
关键词: Breast cancer ; HER2 ; Neoadjuvant chemotherapy ; Tumor-infiltrating lymphocytes ; Predictive factors ; Prognostic factors
刊名: BREAST CANCER RESEARCH AND TREATMENT
发表日期: 2015-11-01
DOI: 10.1007/s10549-015-3617-7
卷: 154, 期:2, 页:239-249
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: PARALLEL HER2-NEGATIVE COHORT ; CONTROLLED SUPERIORITY TRIAL ; ADJUVANT TRASTUZUMAB ; ESTROGEN-RECEPTOR ; PLUS TRASTUZUMAB ; SURVIVAL ; THERAPY
英文摘要:

The purpose of the present study was to determine the optimal threshold for stromal tumor-infiltrating lymphocytes (TILs) and investigate its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy (NAC). Levels of stromal TILs were evaluated using hematoxylin and eosin-stained sections of core biopsies from 116 patients. We investigated the correlation between stromal TILs and pathological response to identify its optimal threshold. Using receiver operating characteristic curve analysis, a 30 % threshold best discriminated pathological complete response (pCR) from non-pCR subgroups (P < 0.001). Lymphocyte-rich breast cancer (LRBC) was defined as having a parts per thousand yen30 % stromal TILs level, and was used for analysis. For analyses of predictive factors, multivariate analysis indicated that LRBC was a strong predictor of pCR with an odds ratio of 5.23 (P < 0.001). Negative hormone receptor (HR) status was also significantly associated with pCR (P = 0.028). LRBC significantly predicted pCR in both HR-positive and HR-negative tumors (P = 0.016 and 0.006, respectively). For survival analyses, LRBC was the only independent predictor of improved event-free survival (EFS) among baseline clinicopathological factors in multivariate analysis (P = 0.012). When pathological response was included, both LRBC and pCR were independent predictors of better EFS (P = 0.040 and 0.045, respectively). LRBC significantly predicted longer EFS in the non-pCR subgroup (P = 0.018), whereas LRBC was not significantly associated with EFS in the pCR subgroup (P = 0.825). A 30 % threshold for stromal TILs optimally identified response to trastuzumab-based NAC in HER2-positive breast cancer; its predictive and prognostic value was also validated in our study.

语种: 英语
所属项目编号: D090507043409010 ; Z131107002213007 ; 2009-1011
项目资助者: Beijing Municipal Science &amp ; Technology Commission ; Beijing Municipal Commission of Health and Family Planning
WOS记录号: WOS:000365188600003
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/55974
Appears in Collections:北京大学第一临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Hosp 1, Breast Dis Ctr, Beijing 100034, Peoples R China
2.Peking Univ, Hosp 1, Dept Pathol, Beijing 100034, Peoples R China
3.Peking Univ, Hosp 1, Dept Med Stat, Beijing 100034, Peoples R China

Recommended Citation:
Liu, Shiwei,Duan, Xuening,Xu, Ling,et al. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy[J]. BREAST CANCER RESEARCH AND TREATMENT,2015,154(2):239-249.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Liu, Shiwei]'s Articles
[Duan, Xuening]'s Articles
[Xu, Ling]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Liu, Shiwei]‘s Articles
[Duan, Xuening]‘s Articles
[Xu, Ling]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace